Foresite Capital is a healthcare and life sciences investment firm with a multidisciplinary team of scientists, engineers, analysts, clinicians and subject matter experts in various disciplines. We work together in a highly collaborative environment, with all investments getting attention from each member of our investment team. Roles at Foresite Capital offer exposure to multiple firms in the healthcare and life sciences industry, and the opportunity to collaborate with top-tier experts in the life sciences, data science and financial industries. We offer competitive salaries, excellent benefits, a flexible work environment, and the opportunity to learn from top thinkers in various disciplines. Foresite Capital is headquartered in San Francisco and is an equal opportunity employer. We thrive on diversity and collaboration.
Foresite Labs supports the next generation of healthcare entrepreneurs who will create innovative companies that transform the way that we discover and develop new medicines, and the way that we deliver care to patients in need. Foresite Labs systematically uses the tools of data science to create companies in healthcare that connect true changes in patient outcomes to all of the activities that are needed to develop, design and deploy therapeutics.
10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.
Adaptimmune LLC is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary T-cell receptor platform that has the potential to transform the treatment of cancer. Established in 2008, the Company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (IPO) in 2015. With U.S. operations based in Philadelphia, PA, Adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast-growing team, click on the careers tab of this page.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet uICT platform technology. Adicet's wholly owned subsidiary, Adicet Bio Israel, Ltd. is developing immunotherapies directed to the disease-specific peptide-MHC complexes associated with different disease indications. Adicet Bio was named by FierceBiotech to its "Fierce 15" Biotech Companies of 2016. Adicet Bio is located in Menlo Park, California.
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care’s modern era. Aetion is based in New York City, and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, and Town Hall Ventures.
Aimmune Therapeutics is a clinical-stage biopharmaceutical company founded to address the unmet medical need in food allergy, which currently has no approved treatments. Our mission is to improve the lives of people with food allergies, based on our proprietary desensitization treatments in development. Aimmune’s lead investigational drug for peanut allergy, AR101, is in Phase 3 clinical testing in North America and Europe. Headquartered in the heart of San Francisco’s biotechnology hub, Brisbane, California, Aimmune has additional offices in the Kings Cross area of London, and in Raleigh, North Carolina.
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.